Suppression of cell-transferred experimental autoimmune encephalomyelitis in defibrinated Lewis rats

被引:38
作者
Inoue, A
Koh, CS
Shimada, K
Yanagisawa, N
Yoshimura, K
机构
[1] SHINSHU UNIV,SCH MED,DEPT MED NEUROL,MATSUMOTO,NAGANO 390,JAPAN
[2] SHINSHU UNIV,SCH MED,RES CTR AGING & ADAPTAT,MATSUMOTO,NAGANO 390,JAPAN
关键词
cell-transferred experimental allergic encephalomyelitis; blood-brain barrier; fibrin deposits; batroxobin;
D O I
10.1016/S0165-5728(96)00150-6
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The role of coagulation-fibrinolysis system in experimental autoimmune encephalomyelitis (EAE) was studied by using batroxobin, derived from the venom of the South American pit viper Bothrops atrox moojeni. Batroxobin converts circulating fibrinogen into an insoluble form and causes a profound degree of afibrinogenemia. Batroxobin treatment (30 BU/kg/day) suppressed clinical signs of cell transferred EAE; the mean cumulative clinical score for batroxobin treated rats was 3.97, while saline treated controls scored 6.9 (P < 0.01). Plasma fibrinogen concentration decreased significantly in batroxobin-treated rats. Histologically, the degree of perivascular mononuclear cell infiltration in the spinal cord was not suppressed in batroxobin-treated rats compared to saline-treated control rats, however, deposition of fibrin around the vessels in the spinal cord was markedly suppressed in batroxobin-treated rats. These findings suggest that batroxobin suppresses EAE by preventing fibrin deposition. and provide evidence that CNS associated deposition oi fibrin and ensuing fibrinolysis, together with increased permeability of blood brain barrier (BBB), are related prerequisites for the clinical manifestation of EAE.
引用
收藏
页码:131 / 137
页数:7
相关论文
共 38 条
[1]  
ADAMS CWM, 1985, INFLAMMATORY VASCULI
[2]   INCREASED PLASMINOGEN ACTIVATOR (UROKINASE) IN TISSUE-CULTURE AFTER FIBRIN DEPOSITION [J].
BERNIK, MB .
JOURNAL OF CLINICAL INVESTIGATION, 1973, 52 (04) :823-834
[3]  
BROWN A, 1982, LAB INVEST, V46, P171
[4]  
BROWN AM, 1981, LAB INVEST, V45, P278
[5]  
EDGINGTON TS, 1985, MONONUCLEAR PHAGOCYT, P687
[6]  
EGBERG N, 1973, Acta Physiologica Scandinavica Supplementum, P1
[7]   FIBRINOLYTIC MECHANISMS AND DEVELOPMENT OF THROMBOLYTIC THERAPY [J].
FLETCHER, AP ;
SHERRY, S ;
ALKJAERSIG, N .
AMERICAN JOURNAL OF MEDICINE, 1962, 33 (05) :738-&
[8]  
FRITZ RB, 1983, J IMMUNOL, V130, P191
[9]  
GECZY CL, 1984, J IMMUNOL, V133, P3026
[10]   EFFECT OF FIBRIN DEGRADATION PRODUCTS ON MICRO-VASCULAR PERMEABILITY [J].
GERDIN, B ;
SALDEEN, T .
THROMBOSIS RESEARCH, 1978, 13 (06) :995-1006